EmblaRestore targets your costlies cardiometabolic conditions through behavioral coaching, low-dose GLP-1s, and structured deprescribing.
Standard programs track weight. They don't track HbA1c, blood pressure, or cholesterol. The conditions driving your costliest claims go unmonitored.
When weight loss improves cardiometabolic markers, medication should come down. Most programs never revisit the medication stack.
Without lab tracking, outcome tiers, and structured reassessment, weight care is a wellness perk. The financial impact stays invisible.
EmblaRestore is a three-tier care model. Each tier builds on the last, moving members from weight reduction to condition management to full cardiometabolic reversal.
Weekly 1:1 coaching. Low-dose GLP-1s prescribed by independent licensed clinicians. Average dose: less than half the standard maximum.
Blood pressure, blood sugar, cholesterol tracked through lab work. Coaching adjusts as markers improve. Medication reviewed at every milestone.
Structured GLP-1 tapering begins at month 16. 78.5% of participants tapered or stopped with no average weight regain.
At enrollment, baseline labs determine the outcome tier. Progress is tracked at every milestone and confirmed at Month 6 with a full employer report.
Blood pressure dropping. Blood sugar stabilizing. Cholesterol moving in the right direction. Still on medication, but markers trending toward normal.
Key lab values in or near healthy range. Fewer medications. Lower risk profile. Clinical deprescribing underway.
Healthy labs without cardiometabolic medication. Normal blood pressure, blood sugar, and cholesterol maintained through behavior change alone.
The TRIM study is Embla's own published research. 2,694 participants. 64 weeks of real-world data. Published in Diabetes, Obesity and Metabolism (Seier et al., 2025). Weight loss comparable to randomized controlled trials, with less than half the medication.
Average weight loss over 64 weeks, across all BMI classes
Tapered or stopped GLP-1s. No average weight regain post-taper.
Average weekly semaglutide dose. Less than half the standard maximum.
Achieved clinically significant weight loss (5%+) across 2,694 participants
"I've lost 40 lbs so far. I've already had to cut my blood pressure medication in half and hope when I do labs again I will no longer be prediabetic. I feel better physically than I have in 10 to 15 years."
Linda, Embla program member
EmblaRestore operates as a true carve-out benefit. No claims feeds. No PBM coordination. No plan amendments. Predictable PEPM pricing. Pay only for engaged members.
Get in touchInterim report at Month 3. Full ROI report at Month 6. 12-month outcome review. Cohort-level data: HbA1c, blood pressure, lipids, weight, medication changes, and tier progression.
Dedicated clinical and coaching contacts for your population. Direct line to the team managing your members.
Every risk has an owner and a protocol. Engagement tracked in real time. Medication renewal tied to coaching check-ins. Same-day escalation for side effects. ~98% member engagement at month 3.
Embla manages enrollment materials, member communications, lab coordination, and all clinical operations. Your team's lift is close to zero.
Let's discuss how EmblaRestore fits into your benefits strategy.
.jpg)